Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447223 | 0.85 | NPC1 (0.44) | FFAR4PLK1 | |
| SCHEMBL17447114 | 0.84 | FFAR4 (0.42) | FFAR4GRIN2BSPRPDE4B | |
| SCHEMBL17447180 | 0.82 | NPC1 (0.41) | FFAR4PDE4B | |
| SCHEMBL28481846 | 0.79 | PLK1 (0.33) | FFAR4PLK1GRIN2BSPRPDE4B | |
| SCHEMBL17447195 | 0.78 | FFAR4 (0.37) | FFAR4PLK1GRIN2BSPR | |
| SCHEMBL17439511 | 0.77 | PDE4B (0.59) | GRIN2BPDE4B | |
| SCHEMBL18578830 | 0.73 | PDE4B (0.33) | FFAR4GRIN2BPDE4B | |
| SCHEMBL17447197 | 0.72 | KHK (0.39) | — | |
| SCHEMBL17447189 | 0.71 | KHK (0.45) | PDE4B | |
| SCHEMBL28484504 | 0.71 | CYP11B2 (0.44) | GRIN2BPDE4BCYP19A1CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008590-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | FFAR4 712/4885ESR1 4505/4885PLK1 939/4885 |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | FFAR4 712/4885ESR1 4505/4885PLK1 939/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | FFAR4 591/4885ESR1 4672/4885PLK1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.